Open-House-Originale-Rabattverträge 2026-04 Cariprazin
Original notice title
Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-04 Cariprazin
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or guaranteed volumes; financial benefit uncertain.
Contract ends automatically on patent or market exclusivity expiry before 30.06.2028.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Enter into discount agreements for Cariprazin
- No exclusivity, uniform conditions
Show full summary
Open-house procedure for concluding discount agreements (Rabattverträge) for the active substance Cariprazin with all qualified pharmaceutical entrepreneurs. No exclusivity, no negotiations. Contract duration up to 24 months for TK, 18 months for HEK, ending 30.06.2028. Joining possible at any time. Not subject to public procurement law.
Risks
No estimated value or guaranteed volumes; financial benefit uncertain.
Contract ends automatically on patent or market exclusivity expiry before 30.06.2028.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (according to §4 Abs. 18 AMG)
- Valid marketing authorization for Cariprazin
- Based in EU/EEA
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House-Originale-Rabattverträge 2026-04 Cariprazin
Conclusion of discount agreements for Cariprazin
Location
Duration
Category
Award Criteria
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff Cariprazin im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff Cariprazin im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 20 May 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 349951-2026
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or guaranteed volumes; financial benefit uncertain.
Contract ends automatically on patent or market exclusivity expiry before 30.06.2028.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications